Lin BioScience, the parent company of Belite Bio raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt Disease

Wednesday, September 16, 2020
NIH Default Logo

Lin BioScience (Taipei Exchange Ticker: 6696), the parent company of Belite Bio, today announced that it has successfully completed its $30 million Rights Issue. The Rights Issue was completed earlier than the scheduled date due to strong oversubscription, with numbers of new institutional investors from Taiwan and overseas participated. The new funding will enable Lin BioScience to continue to invest in Belite Bio to pursue the Phase 3 clinical trial of its lead RBP4 antagonist LBS-008 for Stargardt disease. 

Read full article.